Skip to main content

Table 2 Age-adjusted breast cancer incidence rates among adolescent and young adults by subtype,a California, 2005 to 2009

From: Occurrence of breast cancer subtypes in adolescent and young adult women

Characteristics

Total

rate (95% CI)b

HR+/HER2-

rate (95% CI)

HR+/HER2+

rate (95% CI)

HR-/HER2+

rate (95% CI)

Triple-negative

rate (95% CI)

Age group (years)

     

   15-24

0.7 (0.6-0.9)

0.3 (0.2-0.4)

0.1 (0.0-0.2)

0.1 (0.0-0.2)

0.1 (0.0-0.2)

   25-29

7.4 (6.8-8.1)

2.5 (2.1-2.9)

1.2 (1.0-1.5)

0.8 (0.6-1.1)

1.5 (1.2-1.8)

   30-34

24.4 (23.2-25.7)

9.0 (8.3-9.8)

4.0 (3.5-4.5)

2.3 (2.0-2.7)

5.2 (4.6-5.8)

   35-39

54.5 (52.7-56.3)

24.0 (22.8-25.2)

7.8 (7.1-8.5)

4.3 (3.8-4.8)

10.0 (9.2-10.8)

Race/ethnicity

     

   White

21.0 (20.2-21.9)

9.2 (8.7-9.8)

3.0 (2.7-3.4)

1.7 (1.5-2.0)

3.8 (3.4-4.1)

   Black

21.8 (19.7-23.9)

7.0 (5.9-8.3)

3.4 (2.6-4.3)

2.0 (1.4-2.8)

6.1 (5.0-7.3)

   Hispanic

15.8 (15.1-16.6)

6.0 (5.6-6.5)

2.4 (2.1-2.7)

1.4 (1.2-1.7)

3.4 (3.1-3.8)

   Asian

19.4 (18.1-20.7)

9.0 (8.2-9.9)

3.2 (2.7-3.8)

1.6 (1.3-2.1)

2.4 (2.0-2.9)

   Incidence rate ratio

     

White

Reference

Reference

Reference

Reference

Reference

Black

1.04 (0.93-1.16)

0.76 (0.63-0.91)

1.11 (0.85-1.44)

1.18 (0.83-1.66)

1.61 (1.31-1.97)

Hispanic

0.75 (0.70-0.81)

0.65 (0.54-0.79)

0.78 (0.60-1.02)

0.83 (0.58-1.17)

0.91 (0.74-1.12)

Asian

0.92 (0.84-1.01)

0.98 (0.87-1.10)

1.05 (0.86-1.28)

0.95 (0.73-1.25)

0.64 (0.52-0.79)

AJCC Stage at diagnosis

    

   I

4.9 (4.6-5.1)

2.5 (2.3-2.6)

0.6 (0.5-0.7)

0.3 (0.3-0.4)

0.7 (0.6-0.8)

   II

8.2 (7.9-8.5)

3.3 (3.0-3.5)

1.2 (1.1-1.4)

0.7 (0.6-0.8)

1.8 (1.7-2.0)

   III

3.7 (3.5-3.9)

1.5 (1.3-1.6)

0.7 (0.6-0.8)

0.4 (0.3-0.5)

0.7 (0.6-0.8)

   IV

1.1 (1.0-1.2)

0.4 (0.4-0.5)

0.2 (0.1-0.2)

0.1 (0.1-0.2)

0.2 (0.2-0.3)

Grade

     

Low

7.5 (7.2-7.8)

4.7 (4.4-4.9)

1.1 (1.0-1.3)

0.3 (0.3-0.4)

0.3 (0.3-0.4)

High

10.2 (9.8-10.6)

2.9 (2.7-3.1)

1.6 (1.4-1.7)

1.2 (1.1-1.3)

3.2 (3.0-3.4)

Tumor size

     

≤2 cm

7.3 (7.0-7.7)

3.6 (3.4-3.8)

1.1 (1.0-1.2)

0.5 (0.4-0.6)

1.1 (1-1.2)

> 2 cm

10.4 (10.0-10.8)

4.0 (3.8-4.2)

1.6 (1.5-1.8)

0.9 (0.8-1.1)

2.4 (2.2-2.5)

Microinvasion

0.2 (0.1-0.2)

c

c

c

c

Diffuse

0.1 (0.1-0.2)

c

c

c

c

Lymph node involvement

    

No

9.3 (9.0 - 9.7)

3.9 (3.7-4.2)

1.2 (1.1-1.3)

0.6 (0.5-0.7)

1.9 (1.8-2.1)

Positive

9.1 (8.8 - 9.5)

3.8 (3.6-4.0)

1.6 (1.4-1.7)

1.0 (0.9-1.1)

1.7 (1.5-1.8)

Prior cancer

     

First primary

17.7 (17.2 - 18.2)

7.4 (7.1-7.7)

2.7 (2.5-2.9)

1.5 (1.4-1.7)

3.3 (3.1-3.6)

Non-first primary

1.9 (1.7 - 2.1)

0.7 (0.6-0.8)

0.3 (0.2-0.3)

0.2 (0.1-0.2)

0.4 (0.3-0.5)

Total

18.9 (18.4 - 19.4)

7.8 (7.5-8.2)

2.8 (2.6-3.0)

1.6 (1.5-1.8)

3.6 (3.4-3.8)

  1. aHuman epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-). b95% confidence interval. cStatistic not displayed because of fewer than 15 cases.